Q-omics provides the consensus-scored TSEN34 profile across patient tissues and cancer cell-line models. TSEN34 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TSEN34 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, TSEN34 protein abundance shows 20,417 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, HNSC, and GBM as cancer lineages where TSEN34 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSEN34 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSEN34 survival associations across molecular data types. TSEN34 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSEN34 RNA expression–survival associations across cancer types. High TSEN34 expression shows unfavorable associations in LIHC, ACC, KICH, LGG and MESO, but favorable associations in SCLC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for TSEN34 RNA expression.
This table summarizes TSEN34 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TSEN34. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSEN34 shows lower tumor expression in KICH and higher tumor expression in HNSC, BLCA, KIRC, LIHC and COAD. The HNSC box plot shows higher TSEN34 RNA expression in tumor versus normal tissue (log2 FC = +0.852, t-test p < 0.001).
This table shows molecular features associated with TSEN34 in patient tissues and cancer cell lines. In patient samples, TSEN34 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TSEN34 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
